Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Dividend Announcements/Distribution
- Dividend increased thanks to positive earnings advance to EUR 0.45 - Majority shareholder family waives disbursement of its dividend

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Berlin, 27. October 2006. Marseille-Kliniken AG, (Prime Standard, ISIN DE 0007783003, MKA) will continue its shareholder-friendly dividend distribution policy this year thanks to the positive development of the Group’s annual profits rise from EUR 6.3 last year to EUR 9.7 million in fiscal year 2005/2006. Management and supervisory board will propose the resolution of a dividend distribution of EUR 0.45 per share at the shareholder meeting slated to be held on December 6, 2006.

The dividend of EUR 0.45 per dividend-eligible share includes a special dividend of EUR 0.20 to be paid in connection with the sale and leaseback transactions contracted in FY 2005/2006.

The Marseille family, who holds a stake of approximately 60% in the company will waive its dividend disbursement this year. As a result, the total amount of dividends to be distributed is reduced by EUR 3.3 million to EUR 2.2 million. The Marseille is foregoing its share in the dividend to commit additional resources to the further acceleration of the company’s expansion and to consequently increase its goodwill.

End of the Ad hoc release

FY 2005/2006: The Marseille-Kliniken AG, (Prime Standard, ISIN DE 0007783003, MKA) is continuing to grow and is recording above-average results. In the financial year of 2005/06 the company’s turnover increased to 210.4 million Euros (previous year: 201.5 million Euros). The EBIT result according to IFRS improved from 23.1 million Euros in the previous year to 25.8 million Euros in the year under review. The company’s annual surplus improved from 6.3 million Euros to 9.7 million Euros. The DVFA/SG (IFRS) adjusted result was 9.3 million Euro in the financial year compared to 8.9 million Euros the previous year. Per share this is equal to a result increase of 0.03 Euro to 0.76 Euro (previous year: 0.73 Euro). The equity capital recorded on the balance sheet is 66.8 million Euros as against 62.6 million Euros in the previous year, which equates to a capital ratio of 20.7% (previous year 15.5%).

@@start.t2@@end of announcement                                                 euro adhoc 27.10.2006 06:58:38

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar:

Further inquiry note:
Marseille-Kliniken AG             Hillermann Consulting
Axel Hölzer                          Christian Hillermann
CEO                                       Investor Relations
Alte Jakobstraße 79/80             Eppendorfer Baum 5
10709 Berlin, Germany             20249 Hamburg, Germany
Tel.: 49-(0)30 / 246 32-400 Tel.: 49-(0)40 / 414 069-13
Fax: 49-(0)30 / 246 32-401 Fax: 49-(0)40 / 414 069-14

Branche: Pharmaceuticals
ISIN:      DE0007783003
WKN:        778300
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Hamburger Wertpapierbörse / official dealing

Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: